MERCK & CO Aktie

 

Amgen and Merck both yield around 2.3% and have surged this year, but one of them is paying its dividend out of thin air while the other has a cash cushion that changes the entire income calculus....

Der Pharmakonzern Merck Co. erwartet, dass sich die Herstellung seines personalisierten Krebsimpfstoffs, den er gemeinsam mit Moderna entwickelt, mit der Zeit beschleunigen lässt. Konzernchef Rob Davis sagte dem Sender CNBC, dass der Prozess derzeit rund sechs Wochen dauert, von der Sequenzierung des Tumors bis zur Auslieferung ans Krankenhaus....

MRK's Keytruda sales growth, earlier-stage launches and expanded indications could boost Q3 results, but biosimilar competition looms in 2028-2029....

Um den gesamten Artikel unter newsbreak.com zu lesen, klicken Sie bitte auf die Überschrift...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck & Co., Inc., Rahway, N.J., USA (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Paul J. Diaz, managing partner at Cressey & Company, will join the Company's Board of Directors effective Nov. 1, 2026. He will stand for election by the company's shareholders in May 2027. With the addition of Mr. Diaz, the Merck board will consist of 14 members. “We are pleased to welcome Paul Diaz to our Board. Paul brings extensive leadership and business expertise in the healthcare industry, and we look forward to his contributions and insights,” said Rob Davis, chairman and chief executive officer. Mr. Diaz is a managing partner at Cressey & Company, a private investment firm focused on investing in and cultivating high-quality health care firms. He previously served as president and chief executive officer of Myriad Genetics, Inc., a leading genetic testing and precision medicine company. Before that, he served as president and chief executiv...

Based on the average brokerage recommendation (ABR), Merck (MRK) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?...

Vaccine and biotechnology names are leading a sharp sector rally, and a small protein-vaccine developer is posting the biggest gain of the group. Novavax (NASDAQ:NVAX) shares recently changed hands at $12.77, up 16%. Also rallying, Moderna (NASDAQ:MRNA) shares are at $219.30, up 11%, a double-digit gain that still trails Novavax stock. Meanwhile, Merck (NYSE:MRK) shares […]...

INVA vs. MRK: Which Stock Is the Better Value Option?...

New York (www.aktiencheck.de) - Merck & Co-Aktienanalyse von J.P. Morgan Securities: JPMorgan habe das Kursziel für die Aktie von Merck & Co Inc. (ISIN: US58933Y1055, WKN: A0YD8Q, Ticker-Symbol: 6MK, NYSE-Symbol: MRK) von 150 auf 165 USD angehoben und das Rating "overweight" bestätigt. Bei den Quartalsergebnissen rechne die Bank mit keinen größeren Überraschungen. [mehr]...

Merck & Co. was blocked from selling a new injectable version of its blockbuster cancer drug Keytruda in several European countries, dealing a setback to the drugmaker's efforts to extend its most important franchise ahead of looming patent expirations....

Merck (MRK) reached $141.94 at the closing of the latest trading day, reflecting a +1.72% change compared to its last close....

Both JNJ and MRK have surged in 2026, but a looming patent cliff and a balance sheet loaded with acquisition debt mean one of these pharma dividends faces a reckoning that retirement investors cannot afford to ignore....

MRK's tulisokibart meets the phase IIb HS study's primary endpoint, with high and medium-dose regimens showing superiority over placebo at week 16....

Merck & Co will den Antikörper Tulisokibart nach positiven Phase-2b-Daten in die finale Phase 3 bringen. In einer Studie mit 149 Patienten mit mittelschwerer bis schwerer Hidradenitis suppurativa (HS) erreichte das Mittel nach 16 Wochen laut Ergebnissen vom August die primären und sekundären Endpunkte....

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, will hold its third-quarter 2026 sales and earnings conference call with institutional investors and analysts at 9:00 a.m. ET on Thursday, Oct. 29. During the call, company executives will provide an overview of Merck's performance for the quarter. Investors, journalists and the general public may access a live audio webcast of the call via this weblink. A replay of the webcast, along with the sales and earnings news release, supplemental financial disclosures and slides highlighting the results, will be available at www.merck.com. All participants may join the call by dialing (800) 369-3351 (U.S. and Canada Toll-Free) or (517) 308-9448 and using the access code 9818590. About Merck At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brough...

MRK's $2.13 billion deal for SPR2015 adds a preclinical KRAS G12D inhibitor to its precision oncology pipeline, targeting a common cancer mutation....

Die Aktie des US-Pharma-Konzerns Merck & Co befindet sich in bestechender Form. Kurzfristig angetrieben durch den Forschungserfolg mit Moderna bei einem personalisierten Hautkrebsimpfstoff, steht der eher defensive Titel vor neuen Rekorden....

FDA expands MRK's Welireg label for advanced kidney cancer, adding a third indication as sales climb and the drug gains wider use....

MRK and Daiichi withdraw an FDA filing for ifinatamab deruxtecan after data falls short, while late-stage studies continue....

KENILWORTH (NJ) (dpa-AFX) - Merck & Co., Inc. (MRK), an American multinational pharmaceutical company, announced on Monday that it has entered into an exclusive global license agreement with SciBr......